MedShadow ArticlesMedical Journals Have Flaws, But Government Oversight Isn’t the FixSuzanne B. Robotti
ADHDINVESTIGATING GENERICS: They Say Their ADHD Meds Aren’t Working. They’re Not Imagining ItEmma Yasinski
Featured ArticlesResourcesControlled Drug Classifications: Schedule I, II, III, IV, VSuzanne B. Robotti
MedShadow ArticlesOpinion: RFK’s “Radical Transparency” Looks More Like A Closed DoorSuzanne B. Robotti
MedShadow ArticlesThe FDA’s New Drug Ad Rules Are Here. Will They Actually Change Anything?Emma Yasinski
MedShadow ArticlesFDA Drug Recalls and Warnings: Websites Selling Illegal GLP-1s, Plus MoreKatie Rowley
MedShadow ArticlesInside the FDA Drug Development Process: The Limits of Clinical Trials in Preventing Side EffectsDaphne Berryhill
MedicationsINVESTIGATING GENERICS: Hundreds Of Drugs Remain On The Market After Fraudulent TrialsEmma Yasinski
MedShadow ArticlesWhat To Know About Cobenfy, First New FDA-Approved Treatment For Schizophrenia in DecadesJessica DiGiacinto
MedShadow ArticlesChoices For The Terminally Ill: FDA’S Expanded Access Program Or Right To Try Act?Jessica DiGiacinto
